Tvardi Therapeutics Files 8-K
Ticker: TVRD · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Tvardi Therapeutics, Inc. (TVRD) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-event
TL;DR
Tvardi Therapeutics filed an 8-K on 10/14/25 for an event on 10/13/25.
AI Summary
Tvardi Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on events that occurred on October 13, 2025. The filing indicates a change in the company's status or operations, though specific details of the event are not provided in this excerpt. The company, formerly known as Cara Therapeutics, Inc., is incorporated in Delaware and based in Sugar Land, Texas.
Why It Matters
This 8-K filing signals a material event for Tvardi Therapeutics, Inc., requiring disclosure to investors and the market.
Risk Assessment
Risk Level: medium — An 8-K filing typically indicates a significant event that could impact the company's stock price, requiring investors to stay informed.
Key Players & Entities
- Tvardi Therapeutics, Inc. (company) — Registrant
- Cara Therapeutics, Inc. (company) — Former company name
- October 13, 2025 (date) — Earliest event date
- October 14, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Sugar Land, Texas (location) — Principal executive offices location
FAQ
What specific event prompted Tvardi Therapeutics, Inc. to file this 8-K?
The provided excerpt does not specify the exact event that triggered the 8-K filing on October 13, 2025, only that it is an 'Other Event'.
When was Tvardi Therapeutics, Inc. formerly known as Cara Therapeutics, Inc.?
The company was formerly known as Cara Therapeutics, Inc. with a name change date of July 21, 2010, and prior to that, Cara Therapeutics Inc. with a name change date of December 13, 2005.
What is the principal executive office address for Tvardi Therapeutics, Inc.?
The principal executive offices are located at 3 Sugar Creek Ctr. Blvd. Suite 525, Sugar Land, Texas 77478.
What is the SIC code for Tvardi Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Tvardi Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the Commission File Number for Tvardi Therapeutics, Inc.?
The Commission File Number for Tvardi Therapeutics, Inc. is 001-36279.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 10 · Accepted 2025-10-14 06:11:33
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 per share TVRD The Nasdaq Stock Marke
Filing Documents
- tm2528638d1_8k.htm (8-K) — 26KB
- tm2528638d1_ex99-1.htm (EX-99.1) — 20KB
- tm2528638d1_ex99-1img01.jpg (GRAPHIC) — 4KB
- 0001104659-25-098908.txt ( ) — 219KB
- tvrd-20251013.xsd (EX-101.SCH) — 3KB
- tvrd-20251013_lab.xml (EX-101.LAB) — 33KB
- tvrd-20251013_pre.xml (EX-101.PRE) — 22KB
- tm2528638d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On October 13, 2025, Tvardi Therapeutics, Inc. issued a press release entitled "Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis." The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TVARDI THERAPEUTICS, INC. Date: October 14, 2025 By: /s/ Imran Alibhai Name: Imran Alibhai Title: Chief Executive Officer